| 4.95 -0.04 (-0.8%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.09 | 1-year : | 6.47 |
| Resists | First : | 5.22 | Second : | 5.54 |
| Pivot price | 4.98  |
|||
| Supports | First : | 4.69 | Second : | 3.9 |
| MAs | MA(5) : | 5.01 |
MA(20) : | 4.97 |
| MA(100) : | 5.21 |
MA(250) : | 5.1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 32.7 |
D(3) : | 40.7 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 16.25 | Low : | 3.49 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RADX ] has closed above bottom band by 38.2%. Bollinger Bands are 83% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.03 - 5.06 | 5.06 - 5.08 |
| Low: | 4.83 - 4.86 | 4.86 - 4.88 |
| Close: | 4.91 - 4.95 | 4.95 - 4.99 |
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Tue, 24 Feb 2026
Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart - TipRanks
Tue, 24 Feb 2026
New radiotherapy BetaBart enters first test in human cancer patients - Stock Titan
Tue, 24 Feb 2026
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) - Sahm
Wed, 18 Feb 2026
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Fri, 13 Feb 2026
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Short Interest Up 112.6% in January - MarketBeat
Mon, 15 Dec 2025
Radiopharm Theranostics Surge: Buy or Sell? - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 1,580 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 434.4 (%) |
| Shares Short | 32 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -3.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -152.2 % |
| Return on Assets (ttm) | -27.8 % |
| Return on Equity (ttm) | -109.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.37 |
| Sales Per Share | 1.58 |
| EBITDA (p.s.) | -4.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -1.33 |
| PEG Ratio | 0 |
| Price to Book value | 495 |
| Price to Sales | 3.11 |
| Price to Cash Flow | -1.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|